Mesa Laboratories Balance Sheet Health
Financial Health criteria checks 3/6
Mesa Laboratories has a total shareholder equity of $150.7M and total debt of $212.2M, which brings its debt-to-equity ratio to 140.8%. Its total assets and total liabilities are $440.4M and $289.6M respectively. Mesa Laboratories's EBIT is $10.7M making its interest coverage ratio 1.4. It has cash and short-term investments of $30.0M.
Key information
140.8%
Debt to equity ratio
US$212.25m
Debt
| Interest coverage ratio | 1.4x |
| Cash | US$29.99m |
| Equity | US$150.73m |
| Total liabilities | US$289.63m |
| Total assets | US$440.36m |
Recent financial health updates
Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15
Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?
Sep 28We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt
Jun 28Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Mar 13Recent updates
A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb
Jul 29Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?
May 03Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?
Mar 15Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?
Dec 05Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?
Sep 28Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Aug 09We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt
Jun 28Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking
May 31A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Apr 12Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Mar 13Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
Dec 20Mesa Laboratories declares $0.16 dividend
Oct 03Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced
Sep 09Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?
Sep 06Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?
Aug 08Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M
Aug 04Mesa Laboratories declares $0.16 dividend
Jul 07A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)
May 06Growth Investors: Industry Analysts Just Upgraded Their Mesa Laboratories, Inc. (NASDAQ:MLAB) Revenue Forecasts By 14%
Apr 09Financial Position Analysis
Short Term Liabilities: MLAB's short term assets ($106.7M) exceed its short term liabilities ($54.9M).
Long Term Liabilities: MLAB's short term assets ($106.7M) do not cover its long term liabilities ($234.8M).
Debt to Equity History and Analysis
Debt Level: MLAB's net debt to equity ratio (120.9%) is considered high.
Reducing Debt: MLAB's debt to equity ratio has increased from 16.6% to 140.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable MLAB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: MLAB is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.6% per year.